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Individualized patient management is rapidly evolving, driven by the emergence 
of insights in discovery, development, regulatory, and comparative effectiveness 
sciences.1-4 The pace of discovery is accelerating, enabled by platforms, including 
“omics”, stem cell biology, network medicine, and medical and biological informatics that 
provide unanticipated insights into pathophysiology.2, 4-6 The integration of these 
paradigms has established a model for identifying the mechanistic underpinnings of 
disease, offering novel opportunities to individualize diagnostics that shape how modern 
therapies are deployed, including markers of disease prognosis, clinical predictors of 
therapeutic responses, and molecular determinants that optimize clinical management.7-
10
 Importantly, deconvolution of physiological circuits is producing a new vanguard of 
molecular therapies that target corrupted pathways at the center of disease 
pathogenesis, individualizing patient care algorithms that optimize benefits and 
minimize adverse effects.7-9, 11, 12 
These technological achievements and innovations come at a price. In the United 
States, the market for biologic therapies will increase by 6.5% per year to >$100 billion 
by 2015.13 At that time, 8 of the top 10 drugs by cost will be biologics, and the current 
rate of growth predicts this class of agents will comprise 40% of drug spending by 
2020.13 Nowhere is this trend more evident than in oncology, in which discovery science 
has produced insights into the pathophysiology underlying neoplasia, yielding new 
diagnostic and therapeutic targets.14 These discoveries have been translated into an 
array of patient management options molecularly targeted to corrupted circuits in 
tumorigenesis. However, the cost of these molecular modalities can approach $100,000 
annually.15 They materially contribute to the doubling of the cost of treating cancer 
patients worldwide.15 Moreover, the escalating price of molecular diagnostics and 
therapeutics is poised to be one dominant driver of the cost curve describing the rate of 
increase in healthcare expenditures in cancer care.15 In that context, the aging of the 
population, associated with an increase in cancer incidence and prevalence, and the 
 4 
cost of patient management will produce a 600% increase in the cost of cancer care in 
the 30 year period ending in 2020, reaching $157 billion in the U.S.15 In an environment 
of economic austerity demanding social responsibility, innovation in the form of 
molecular medicine must both improve the quality of patients’ lives and the societal 
value proposition of healthcare management, each in an evidence-based affordable 
fashion. Absence of either element risks creating a healthcare system characterized by 
tiered access to innovation, limited only to a small group of the most economically 
advantaged, with rationing of the products of molecular medicine to other citizens. 
Technology and innovation in molecular medicine have created an imperative that 
patient management must be socially responsible, cost effective, and sustainable.15 
While the revolution in technology is transforming diagnostic and therapeutic 
approaches for individual patients, the impact of this innovation on the societal 
healthcare value proposition is more ambiguous. This can best be appreciated by 
considering four recently approved molecularly targeted agents, in the context of their 
efficacy and cost. Sipuleucel-T (Provenge; Dendreon Corporation) is a therapeutic 
vaccine for metastatic hormone resistant prostate cancer. Dendritic cells isolated from 
patients are incubated with a fusion protein consisting of the prostatic acid phosphatase 
tumor antigen and granulocyte-macrophage colony stimulating factor ex vivo, followed 
by their re-infusion into patients.16 A complete Sipuleucel-T treatment repeats three 
courses over one month. Regulatory approval of Sipuleucel-T was based on the 
IMPACT trial, which enrolled 512 patients with asymptomatic or minimally symptomatic 
metastatic hormone resistant prostate cancer. Median survival for patients treated with 
Sipuleucel-T was improved by ~4 months, to 25.8 months compared to 21.7 months for 
placebo-treated patients, reflecting a statistically significant improvement in overall 
survival (P=0.032).16 A course of Sipuleucel-T treatment costs ~$100,000.15 
Abiraterone (Zytiga; Johnson & Johnson) also is a new molecularly targeted 
agent for hormone-resistant prostate cancer. Abiraterone inhibits CYP17A1, an enzyme 
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expressed in testicular, adrenal, and prostatic tumor tissues. CYP17 catalyzes two 
sequential reactions in the biosynthesis of androgens, including the conversion of 
pregnenolone and progesterone to their 17-α-hydroxy derivatives by its 17 α-
hydroxylase activity, and the subsequent formation of dehydroepiandrosterone (DHEA) 
and androstenedione, respectively, by its C17,20 lyase activity.17 DHEA and 
androstenedione are androgens and precursors of testosterone. Inhibition of CYP17 
activity by abiraterone decreases circulating levels of testosterone.18 In Phase III trials, it 
extended median survival almost 4 months, to 14.8 months compared to 11.2 months in 
placebo-treated, supporting its regulatory approval following an expedited six-month 
review.19 Treatment costs for abiraterone are ~$5,000 each month.19 
Vemurafenib (Zelboraf; Daiichi Sankyo and Hoffmann–La Roche) is a new 
targeted agent for the treatment of late stage melanoma.20 Vemurafenib induces 
programmed cell death in melanoma cell lines by inhibiting B-Raf common V600E 
mutation.21 Indeed, vemurafenib only works in melanoma patients whose tumor carries 
the V600E BRAF mutation, in which the amino acid at position 600 on the B-Raf protein 
is glutamate, rather than the normal valine. Of patients with melanoma, ~60% carry this 
mutation. In striking contrast, melanoma cells without this mutation are not inhibited by 
vemurafenib, and the drug paradoxically stimulates normal BRAF and may promote 
tumor growth in such cases.22 Vemurafenib was approved for the treatment of 
unresectable or metastatic BRAF V600E-positive melanoma, based on a phase III study 
of 675 patients who were randomized to either vemurafenib or dacarbazine.23 
Progression free survival was improved nearly 4 months, from 1.6 months in 
dacarbazine-treated patients to 5.3 months in those treated with vemurafenib, and 
objective response rate (48% vs. 4%) were all significantly better on the vemurafenib 
arm.19 Treatment costs for vemurafenib are ~$10,000 each month.19 
Ipilimumab (Yervoy; Bristol-Myers Squibb) is a fully human monoclonal antibody 
that also has been approved for late stage melanoma. Ipilimumab targets cytotoxic T-
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lymphocyte-associated antigen 4 (CLTA-4), which is a negative regulator of T cell-
dependent immune responses.19 Ipilimumab blocks CTLA-4, enhancing T-cell mediated 
anti-tumor activity.19 Approval of ipilimumab was based on a phase III trial of 676 
patients with unresectable or metastatic disease demonstrating an improvement of 
survival of ~4 months, from 6.4 months for control-treated patients, to 10 months for 
those treated with ipilimumab.24 Treatment costs for ipilimumab are ~$30,000 per 
dose.19 
These recently approved targeted agents highlight a common theme of molecular 
therapies emanating from the new biology: modest clinical improvement, here 
measured in months of survival, with relatively high costs, approaching ~$100,000. 
Modest benefit for high cost establishes an ambiguous value proposition for these 
innovations in the context of individual patients, the healthcare system and society. For 
patients and their families, the opportunity to gain months of survival can be a miracle 
for those with a terminal disease facing imminent death, with a value that is beyond 
quantification. This philosophy aligns closely with those who consider decisions about 
individual resource allocation to be the strict province of patients and their families, 
rather than governments and societies. Moreover, in the U.S., this philosophy has been 
facilitated by policies surrounding healthcare financing, which consider safety and 
efficacy, but not the cost-benefit ratio. This system creates a moral hazard in which 
consumers (patients) insulated from the financial burden of the product are incented to 
utilize marginally effective resources.15 
The value proposition of molecular innovations for individual patients contrasts 
with that for healthcare systems and societies. The over-arching objective of societal 
policies generally is to achieve the greatest good for the greatest number of citizens. 
With respect to healthcare policies, this translates into balancing access, quality, equity 
and cost.15 For example, the UK guarantees access to healthcare to all citizens, but the 
availability of specific interventions in the marketplace is defined by formulaic 
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quantification of costs and benefits. At the other end of the spectrum, the U.S. 
guarantees the availability in the marketplace of all interventions that are safe and 
effective, regardless of cost, but patient access to those interventions is not universal. 
These differences in approaches to healthcare finance underscore the imperative that 
policies concerning the value of innovation are ultimately shaped by societal concepts of 
the value of health and specific clinical outcomes.15 Regardless of the healthcare model, 
each operates in an environment of limited resources, requiring cost-benefit analyses of 
the value of innovation and the anticipated improvements in health. Importantly, they 
must consider an inherent choice required by constrained resources: whether those 
improvements are worth the trade-off in healthcare benefits lost by other modalities 
displaced by the added cost of innovation.15 
These observations highlight the imminent challenge of deploying the advancing 
wave of innovation in molecularly medicine to manage patients. They underscore the 
importance of establishing the evidence base for the value of new therapeutics by not 
only qualifying their ability to improve patient outcomes, but also quantifying that 
improvement (how much) and the likelihood of its achievement.1, 15 They recognize that 
the value of these improvements in clinical outcomes is not a universal construct with 
global applicability but, rather, society-specific, in part, defined by relative economies 
and models of healthcare finance. They consider whether the deployment of these 
modalities improves the overall value proposition of the healthcare system. Indeed, 
molecularly targeted agents that prevent recurrent cancer relieve the economic burden 
of treating future advanced disease. Moreover, they consider the value of molecular 
therapies in the context of whether their quantitative outcomes are worth the healthcare 
benefits lost by economic displacement of other healthcare initiatives. 
We are in the midst of a revolution in disease management established by 
emerging innovations in platform technologies, where clinical outcomes are resolved by 
targeted molecular diagnostics and therapeutics. This evolving paradigm has already 
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yielded products that have advanced into the healthcare marketplace. In the context of 
worldwide economic realities and constrained healthcare resources, it is essential to 
establish the value proposition of targeted diagnostics and therapeutics, to ensure their 
benefits are maximized for patients, populations and societies.3 
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